2018 is a key year in the development of Evgen Pharma Plc (LON:EVG), the Cheshire-based business which has made rapid progress since joining AIM.
It now has two Phase II clinical trials underway, one in advanced breast cancer and one in a type of stroke known as a subarachnoid haemorrhage (SAH).
Evgen was founded in 2007 to have a lower risk profile than many in its peer group. Its drug pipeline is based on sulforaphane, a naturally occurring molecule originating in brassicas such as broccoli. A huge amount of academic research has been published on sulforaphane, highlighting its potential in medical conditions ranging from solid tumour cancers through multiple sclerosis, Parkinson’s disease and autism.